Showing 1 to 1 of 1 results
dutchnews.nl
🌐 85% Global Worthiness
Dutch Insurers Limit Coverage of Two Breast Cancer Drugs
Dutch health insurers ended full coverage for two expensive breast cancer drugs (ribociclib and abemaciclib), impacting 2,000 women, due to high costs and a price negotiation failure with drug manufacturers, despite oncologists' concerns about differing drug effectiveness and side effects.
Dutch Insurers Limit Coverage of Two Breast Cancer Drugs
Dutch health insurers ended full coverage for two expensive breast cancer drugs (ribociclib and abemaciclib), impacting 2,000 women, due to high costs and a price negotiation failure with drug manufacturers, despite oncologists' concerns about differing drug effectiveness and side effects.
Progress
48% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results